Ocular Therapeutix CEO presents OTX-TKI program at EURETINA conference

OCULAR THERAPEUTIX, INC

CEO Antony Mattessich presented on OTX-TKI for wet AMD at EURETINA Innovation Spotlight on Oct 4, 2023.
Presentation provided an overview of the investigational tyrosine kinase inhibitor therapy for retinal vascular diseases.
No new clinical data, financial guidance, or material updates were disclosed in the slides.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.